Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137436
Status:
COMPLETED
Last Update Posted:
2011-08-29
First Post:
2005-08-26
Brief Title:
Study Of SU011248 In Combination With Docetaxel Taxotere And Prednisone In Patients With Prostate Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 12 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel Taxotere And Prednisone In Patients With Metastatic Hormone Refractory Prostate Cancer HRPC
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center open-label Phase 12 study of SU011248 sunitinib malate SUTENT in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer mHRPC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None